Search

Your search keyword '"Perrin, Christophe"' showing total 15 results
Start Over Author "Perrin, Christophe" Language undetermined
15 results on '"Perrin, Christophe"'

1. Additional file 1 of Prone position versus usual care in hypoxemic COVID-19 patients in medical wards: a randomised controlled trial

Author

Nay, Mai-Anh, Hindre, Raphaël, Perrin, Christophe, Clément, Jérémy, Plantier, Laurent, Sève, Aymeric, Druelle, Sylvie, Morrier, Marine, Lainé, Jean-Baptiste, Colombain, Léa, Corvaisier, Grégory, Bizien, Nicolas, Pouget-Abadie, Xavier, Bigot, Adrien, Jamard, Simon, Nyamankolly, Elsa, Planquette, Benjamin, Fossat, Guillaume, and Boulain, Thierry

Abstract

Additional file 1. Protocol.

Published
2023
Full Text
View/download PDF

2. Additional file 2 of Prone position versus usual care in hypoxemic COVID-19 patients in medical wards: a randomised controlled trial

Author

Nay, Mai-Anh, Hindre, Raphaël, Perrin, Christophe, Clément, Jérémy, Plantier, Laurent, Sève, Aymeric, Druelle, Sylvie, Morrier, Marine, Lainé, Jean-Baptiste, Colombain, Léa, Corvaisier, Grégory, Bizien, Nicolas, Pouget-Abadie, Xavier, Bigot, Adrien, Jamard, Simon, Nyamankolly, Elsa, Planquette, Benjamin, Fossat, Guillaume, and Boulain, Thierry

Abstract

Additional file 2. Supplementary files.

Published
2023
Full Text
View/download PDF

3. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort

Author

Frank, Sophie, Carton, Matthieu, Dubot, Coraline, Campone, Mario, Pistilli, Barbara, Dalenc, Florence, Mailliez, Audrey, Lévy, Christelle, D'Hondt, Veronique, Debled, Marc, Vermeulin, Thomas, Coudert, Benoit, Perrin, Christophe, Gonçalves, Anthony, Uwer, Lionel, Ferrero, Jean-Marc, Eymard, Jean-Christophe, Petit, Thierry, Mouret-Reynier, Marie-Ange, Patsouris, Anne, Guesmia, Tahar, Bachelot, Thomas, Robain, Mathieu, Cottu, Paul, D’Hondt, Véronique, Institut Curie [Paris], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Institut Gustave Roussy (IGR), Département de médecine oncologique [Gustave Roussy], Institut Claudius Regaud, Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Institut du Cancer de Montpellier (ICM), Institut Bergonié [Bordeaux], Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), Centre Eugène Marquis (CRLCC), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Institut Jean Godinot [Reims], Centre Paul Strauss, CRLCC Paul Strauss, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), Centre Léon Bérard [Lyon], Institut Curie [Saint-Cloud], French Breast Cancer Intergroup - UCBG [Paris] (R&D UNICANCER), R&D Unicancer [Paris], Cohortes épidémiologiques en population (CONSTANCES), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Paris (UP), Département d'Oncologie Médicale [Institut Curie, Paris], Centre de Lutte Contre le Cancer Nantes Atlantique 'René Gauducheau' (CLCC), Université Lille Nord de France (COMUE)-UNICANCER, Service d'Oncologie médicale [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Université Catholique de Louvain = Catholic University of Louvain (UCL), Service d'Oncologie Médicale, UNICANCER-UNICANCER, Hôpital Charles Nicolle [Tunis], Département d'oncologie médicale [Rennes], CRLCC Eugène Marquis (CRLCC), Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), Senescence Escape and Soluble Markers of Cancer Progression (CRCINA-ÉQUIPE 12), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Oncogénèse et progression tumorale, Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de recherche translationnelle, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université Paris Cité (UPC), Université Côte d'Azur (UCA)-UNICANCER, and Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes (UN)-Université d'Angers (UA)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes (UN)-Université d'Angers (UA)

Subjects
Adult, Oncology, medicine.medical_specialty, Receptor, ErbB-2, [SDV]Life Sciences [q-bio], Age at diagnosis, Breast Neoplasms, Triple Negative Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, lcsh:RC254-282, Cohort Studies, Metastatic disease, 03 medical and health sciences, Age Distribution, Breast cancer, Age, 0302 clinical medicine, Internal medicine, Overall survival, Humans, Medicine, 030212 general & internal medicine, Stage (cooking), skin and connective tissue diseases, Early Detection of Cancer, Retrospective Studies, business.industry, Cancer, General Medicine, Middle Aged, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Survival Analysis, Metastatic breast cancer, Real-world data, 3. Good health, Young age, 030220 oncology & carcinogenesis, Cohort, Original Article, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Surgery, France, business
Abstract

Background Young age is a poor prognostic factor in early stage breast cancer (BC) but its value is less established in metastatic BC (MBC). We evaluated the impact of age at MBC diagnosis on overall survival (OS) across three age groups ( 60 years(y)). Methods ESME MBC database is a national cohort, collecting retrospective data from 18 participating French cancer centers between January 01, 2008 and December 31, 2014. Results Among 14 403 women included, 1077 (7.5%), 6436 (44.7%) and 6890 (47.8%) pts were 60 y respectively. Pts 60y) and triple negative subtypes (27.4 vs 14.6% in >60y), and more frequent visceral involvement (36.3 vs 29.8% in >60y). At a median follow-up of 48 months, median OS differed across age groups: 38.8, 38.4 and 35.6 months for pts 60y, respectively (p 60y, respectively (p, Highlights • Young age is a poor prognosis factor in early stage breast cancer. • Young age is associated with an aggressive presentation in metastatic breast cancer. • Young age had no impact on overall survivall in metastatic breast cancer. • Oppositely, older women (>60y) had a stightly poorer prognosis at the metastatic stage.

Published
2020

4. COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome

Author

Dietz, Matthieu, Chironi, Gilles, Claessens, Yann-Erick, Farhad, Ryan Lukas, Rouquette, Isabelle, Serrano, Benjamin, Nataf, Valérie, Hugonnet, Florent, Paulmier, Benoît, Berthier, Frédéric, Keita-Perse, Olivia, Giammarile, Francesco, Perrin, Christophe, Faraggi, Marc, Fissore-Magdelein, C., Gabriel-Solean, S., Dahmani, B., Riss, I., Sorlin, P., Dupasquier, V., Pathak, A., Dugourd, C., Nicolai, M., Rijo, N., Beau, N., Magdelein, X., Olyve, F., Chaillou-Orpitz, S., Lépine, J., Lorillou, M., Maincent, C., Bertrand, S., Brunner, P., Dittlot, C., Fuerxer, F., Liberatore, M., Armando, G., Bouregba, M., Catineau, J., Garcia, P., and Tran, D.

Subjects
Male, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Glucose uptake, Inflammation, Gastroenterology, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Lung, Aged, Aged, 80 and over, business.industry, COVID-19, Heart, General Medicine, Middle Aged, medicine.disease, FDG PET/CT, Pneumonia, Treatment Outcome, medicine.anatomical_structure, Radiology Nuclear Medicine and imaging, Anaerobic glycolysis, Original Article, Female, Lymph Nodes, Lymph, Bone marrow, Radiopharmaceuticals, medicine.symptom, business
Abstract

Purpose [18F]-2-Fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT) is a sensitive and quantitative technic for detecting inflammatory process. Glucose uptake is correlated with an increased anaerobic glycolysis seen in activated inflammatory cells such as monocytes, lymphocytes, and granulocytes. The aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for COVID-19. Methods Patients admitted with COVID-19 were prospectively enrolled. FDG PET/CT was performed from day 6 to day 14 of the onset of symptoms. Depending on FDG PET/CT findings, patients’ profiles were classified as “inflammatory” or “low inflammatory.” FDG PET/CT data were compared with chest CT evolution and short-term clinical outcome. All inflammatory sites were reported to screen potential extra-pulmonary tropism. Results Thirteen patients were included. Maximum standardized uptake values ranged from 4.7 to 16.3 in lungs. All patients demonstrated increased mediastinal lymph nodes glucose uptake. Three patients (23%) presented mild nasopharyngeal, two patients (15%) bone marrow, and five patients (38%) splenic mild increase in glucose uptake. No patient had significant digestive focal or segmental glucose uptake. There was no significant physiological myocardial glucose uptake in all patients except one. There was no correlation between PET lung inflammatory status and chest CT evolution or short-term clinical outcome. Conclusion Inflammatory process at the presumed peak of the inflammatory phase in COVID-19 patients is obvious in FDG PET/CT scans. Glucose uptake is heterogeneous and typically focused on lungs. Trial registration NCT04441489. Registered 22 June 2020 (retrospectively registered). Electronic supplementary material The online version of this article (10.1007/s00259-020-04968-8) contains supplementary material, which is available to authorized users.

Published
2020

5. And the Doctor Answers: 'Dream, Dream, I Will Be the Guardian of Your Breathing…'

Author

Rabec, Claudio, Gonzalez-Bermejo, Jésus, Perrin, Christophe, Langevin, Bruno, Pepin, Jean-Louis, Rodenstein, Daniel, Janssens, Jean Paul, SomnoNIV group, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, and UCL - (SLuc) Service de pneumologie

Subjects
ddc:616, Pulmonary and Respiratory Medicine, Medical education, medicine.medical_specialty, business.industry, Respiration, media_common.quotation_subject, Alternative medicine, MEDLINE, Dreams, Neurology, Physicians, Family medicine, Guardian, Breathing, Humans, Medicine, Neurology (clinical), Dream, business, media_common
Published
2016

6. Essential Medicines at the National Level: The Global Asthma Network’s Essential Asthma Medicines Survey 2014

Author

Bissell, Karen, Ellwood, Philippa, Ellwood, Eamon, Chiang, Chen-Yuan, Marks, Guy B., El Sony, Asma, Asher, Innes, Billo, Nils, Perrin, Christophe, Asher, I, Billo, N. E., Bissell, K., Chiang, C-Y, El Sony, A., Ellwood, P., Garcia-Marcos, L., Mallol, J., Marks, G. B., Pearce, N., Strachan, D., Priftanji, A., Boukari, R., Taright, S., Gomez, M., Baghdasaryan, A., Burgess, S., Mattes, J., Tai, A., Riedler, J., Shpakou, A., Weyler, Joost J., Lawin, H., de Abruzzese, Aguirre J., Domuz, S., Brandao, H., V, Camargos, P. A. M., Fischer, G. B., Menezes, A. M., Porto Neto, A. C., Rosario, N., Sole, D., Mustakov, T. B., Birba, E., Ngahane, Mbatchou B. H., Tse, S. M., Standring, P., Aguirre, V, Calvo Gil, M. A., Chen, Y-Z, Kan, X., Garcia, E., Niederbacher, J., Obel, Kabengele B., Soto-Quiros, M. E., Banac, S., Yiallouros, P., Lochte, L., Barba, S., Bustos, C., El Falaki, M., Figueroa Colorado, M., Weihe, P., Lal, V. A., Makela, M., Annesi-Maesano, I, Raherison, C., Gotua, M., von Mutius, E., Addo-Yobo, E. O., Akpinar-Elci, M., Lai, C. K. W., Novak, Z., Kabra, S. K., Ilangho, R. P., Pherwani, A., V, Sharma, S. K., Sukumaran, T. U., Dalimunthe, W., Karimi, M., Masjedi, M-R, Manning, P., Shohat, T., Forastiere, F., La Grutta, S., Petronio, M. G., Piffer, S., Kahwa, E., Odajima, H., Abu-Ekteish, F., Amukoye, E. I., Esamai, F. O., Hong, S-J, Neziri-Ahmetaj, L., Momen, J. A., Akkhavong, K., Svabe, V, Vlaski, E., Mortimer, K., Daud, M., Montefort, S., Del Rio Navarro, B. E., Jimenez Gonzalez, C. A., Merida-Palacio, J., V, Paramo-Arroyo, R. F., Munkhbayarlakh, S., Brunekreef, B., Currie, S., Douwes, J., Graham, D., Hancox, R., Moyes, C., Pattemore, P., Vis, K., Cordero, Rizo M. Z., Ayuk, A., Falade, A. G., Garba, Ilah B., Hammangabdo, A., Onyia, N., Pulu, M., Nystad, W., Al-Rawas, O., Yusuf, M. O., Watson, B. M., El Sharif, N., Cukier, G., Chiarella, P., Pagcatipunan, R., Breborowicz, A., Lis, G., Morais-Almeida, M., Deleanu, D., Kamaltynova, E., Kondiurina, E. G., Esera-Tulifau, L., Al-Ghamdi, Memish, Z. A., Nahhas, M. A., Yousef, A., Toure, N. O., Visnjevac, D., Zivkovic, Z., Deen, G. F., Goh, D. Y. T., Masekala, R., Zar, H. J., Carvajal-Uruena, I, Gonzalez Diaz, C., Korta Murua, J., Luna-Paredes, C., Morales-Suarez-Varela, M., Praena-Crespo, M., Kudagammana, S. T., Mohammad, Y., Guo, Y. L., Huang, J-L, Lao-Araya, M., Teeratakulpisarn, J., Vichyanond, P., Anderson, S., Tidjani, O., Iosefa, T., Aho, G., Dookeeram, D., Hamzaoui, A., Yorgancioglu, A., Ituaso-Conway, N., Worodria, W., Fedortsiv, O., Mahboub, B., Mansur, A. H., Kumar, H., Valentin-Rostan, M., Harrison, G., Fiocchi, A., Le, L. T. T., Wa Somwe, S., Manangazira, P., Global Asthma Network Study Grp, Department of Dermatology, Allergology and Venereology, Clinicum, and HUS Inflammation Center

Subjects
noncommunicable diseases, Cross-sectional study, Health, Toxicology and Mutagenesis, 030231 tropical medicine, MEDLINE, lcsh:Medicine, LOW-INCOME, Inhaled corticosteroids, essential medicines, Disease, World Health Organization, Article, Essential medicines, 03 medical and health sciences, access, 0302 clinical medicine, Surveys and Questionnaires, Environmental health, medicine, Humans, Anti-Asthmatic Agents, 030212 general & internal medicine, Biology, Reimbursement, Asthma, CHALLENGES, business.industry, AVAILABILITY, lcsh:R, Public Health, Environmental and Occupational Health, asthma, medicine.disease, bronchodilators, 3. Good health, Chemistry, Cross-Sectional Studies, national reimbursement list, 3121 General medicine, internal medicine and other clinical medicine, Action plan, sense organs, Human medicine, inhaled corticosteroids, Drugs, Essential, business
Abstract

Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low- and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013&ndash, 2020 sets an 80% target for essential NCD medicines&rsquo, availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013&ndash, 2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses&mdash, 41 high-income countries and territories (HICs), 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system&rsquo, s capacity to address NCDs.

Published
2019

7. Roms. Du génocide oublié à la mémoire retrouvée

Author

Califano, Benoît, Perrin, Christophe, Stitou, Emmanuelle, and Teulières, Laure

Subjects
Cultural Studies, History, Sociology and Political Science, Demography
Abstract

Califano Benoît, Perrin Christophe, Stitou Emmanuelle, Teulières Laure. Roms. Du génocide oublié à la mémoire retrouvée. In: Diasporas. Histoire et sociétés, n°6, 2005. Migrations en mémoire. pp. 161-165.

Published
2005

14. Sur l’anticartésianisme prétendu de Heidegger : le sens d’(une) Auseinandersetzung

Author

Perrin, Christophe

Subjects
Heidegger, Martin (1889-1976), Heidegger, 1 - Filosofía y psicología
Abstract

Réservant à la pensée de Descartes un traitement plus réservé que l’étude qu’il peut mener de ses autres grands devanciers, Heidegger, à en croire certains commentateurs, dissimulerait mal envers le penseur français son inimitié, celle-ci le prémunissant sans doute du danger de ne pouvoir se relever d’un « cartésianisme inné », dont il fait le reproche aux philosophes. C’est pourtant contre ce préjugé qu’il s’agit ici de lutter en désamorçant, à travers l’éclaircissement de la notion d’Auseinandersetzung, cet apparent paradoxe : entrant toujours en confrontation avec ses ‘’prédécesseurs’’, jamais pourtant Heidegger n’entre en conflit avec eux.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results